Clinical Trial Application(CTA)
A regulatory submission to EU or non-US authorities seeking authorization to conduct a clinical trial of an investigational medicinal product.
Usage Examples
- The sponsor filed the EU CTA through CTIS the same week as the US IND.
- Part I assessment returned questions about the IMPD; Part II ethics review ran in parallel.
- Health Canada's CTA for the Phase 2 trial was authorized within 30 days.
What is CTA?
A Clinical Trial Application (CTA) is the submission sponsors file with EU member state authorities (or comparable non-US regulators) to obtain authorization to conduct a clinical investigation of a drug or biologic. In the EU, CTAs are now filed through the Clinical Trials Information System (CTIS) under the Clinical Trials Regulation (EU) No 536/2014, which consolidated the prior country-by-country process into a single harmonized EU-wide submission.
The CTA is conceptually similar to a US IND but operationally distinct: it is filed with the EU rather than FDA, uses a different application structure, and follows the EU regulatory framework for clinical research. CTAs require authorization from both the national regulatory authority (Part I assessment) and the relevant ethics committee (Part II assessment) before a trial may begin.
Canada uses a Clinical Trial Application for similar purposes under Health Canada oversight, as do many other non-US jurisdictions. Sponsors running global trials typically file an IND in the US, a CTA in the EU, CTAs in other target countries, and align protocol content across jurisdictions to minimize inconsistency.
Regulatory Context
This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside REGULATION EU 536 2014, DIRECTIVE 2001 20 EC.
When This Matters
- The sponsor filed the EU CTA through CTIS the same week as the US IND.
- Part I assessment returned questions about the IMPD; Part II ethics review ran in parallel.
- Health Canada's CTA for the Phase 2 trial was authorized within 30 days.
Common Mistakes
- Treating submission readiness as a formatting-only check without lifecycle validation.
- Using outdated guidance references across modules and summaries.
- Missing cross-functional review between RA, CMC, and quality before submission.
Related Regulations
Frequently Asked Questions
A CTA is filed with EU member state authorities or non-US regulators; an IND is filed with FDA. The content requirements overlap (ICH-aligned Investigator's Brochure, protocol, CMC data) but the submission structure and review process differ. A single global trial typically requires both.
The Clinical Trials Information System (CTIS) is the EU-wide portal for submitting and managing clinical trial applications under Regulation 536/2014. It replaced the country-by-country CTA process with a single harmonized submission accessible to all EU member states.
Under the EU Clinical Trials Regulation, initial assessment takes up to 45 days for standard applications. Applicants may have additional 22 days to respond to questions. Total timeline to authorization typically runs 60-90 days. Health Canada CTAs are authorized within 30 days by default.
Related Terms
Related Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
Track ICH quality guidelines automatically and get alerts when changes impact your products
Related Regulatory Intelligence
Related Actions
Sources & References
